- Home
- PII vs DNLI Comparison
PII vs DNLI Comparison
Compare PII & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PII | DNLI |
|---|---|---|
| Founded | 1954 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 2.5B |
| IPO Year | 1987 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PII | DNLI |
|---|---|---|
| Price | $67.80 | $18.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $52.80 | $32.58 |
| AVG Volume (30 Days) | 788.8K | ★ 1.7M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,076,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.13 | $3,993.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.92 | $10.57 |
| 52 Week High | $75.25 | $24.35 |
Technical Indicators
Market Signals| Indicator | PII | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 51.69 |
| Support Level | $66.18 | $17.20 |
| Resistance Level | $71.25 | $20.61 |
| Average True Range (ATR) | 2.29 | 1.03 |
| MACD | 0.35 | -0.21 |
| Stochastic Oscillator | 62.55 | 29.72 |
Price Performance
Historical ComparisonAbout PII Polaris Inc.
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.